The next three years will be a proving period for Astellas. Its new Corporate Strategic Plan […]
Is Shionogi going global as a pharmaceutical company from Japan, or simply buying growth while its […]
Takeda’s savings programme is no longer an abstract investor slide. It has moved from corporate language […]
The recent regulatory changes in Japan’s pharmaceutical sector present a significant opportunity for non-Japanese companies. By […]